NEUROPACE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.91 USD | +5.66% |
|
-8.23% | -32.98% |
| 05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
| 05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Compared values
| Sector | Change | 5d. change | 1st Jan change | 1-year change | 5-years change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| NEUROPACE, INC. | Other Advanced Medical Equipment & Technology | +5.66% | -8.23% | -32.98% | +55.28% | - | 199M |  | |  |
Technical Rankings Surperformance
- Stock Market
- Equities
- NPCE Stock
- Charts NeuroPace, Inc.
- Comparison Chart
